Drug intelligence / Profile preview

BR1018A-1

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR1018A-1 is a code-named pharmaceutical agent developed by Boryung Corp. It is a component of a larger four-drug combination, BR1018, which is being investigated for the treatment of essential hypertension and primary hypercholesterolemia. Clinical trials indicate that BR1018A-1 can be administered alone or co-administered with other components of the BR1018 combination. The full BR1018 combination is known to comprise fimasartan, amlodipine, atorvastatin, and ezetimibe.

Beyond the preview

Go deeper on BR1018A-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1018A-1.

Explore the full profile